News
ONVO
0.8084
-3.76%
-0.0316
Weekly Report: what happened at ONVO last week (0610-0614)?
Weekly Report · 4d ago
Weekly Report: what happened at ONVO last week (0603-0607)?
Weekly Report · 06/10 10:53
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024
Organovo Holdings reported earnings per share of -29 cents for the fourth quarter of 2024. The company reported revenue of $29,000. This was 99.96% worse than the analyst estimate of $75.00 million. Organovo Holdings is a biopharmaceutical company.
Investorplace · 06/03 15:52
Weekly Report: what happened at ONVO last week (0527-0531)?
Weekly Report · 06/03 10:56
Weekly Report: what happened at ONVO last week (0520-0524)?
Weekly Report · 05/27 11:00
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Organovo Holdings, Inc. Is a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease. Data from a poster presented at Digestive Disease Week (DDW2024) shows potential of FXR314 in combination with tofacitinib for treating ulcerative colitis.
Barchart · 05/21 07:05
Weekly Report: what happened at ONVO last week (0513-0517)?
Weekly Report · 05/20 10:54
Organovo Granted U.S. Patent #11982668: Use Of Engineered Renal Tissues In Assays
Benzinga · 05/14 16:56
Weekly Report: what happened at ONVO last week (0506-0510)?
Weekly Report · 05/13 11:02
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
AppLovin Corporation shares jumped 14.8% in today's pre-market trading. The company reported better-than-expected first-quarter financial results. Pop Culture Group Co., Ltd. Shares rose 60.3% to $2.71 in pre- market trading.
Benzinga · 05/09 12:13
Organovo Holdings, Inc. Announces Pricing Of $5.25M Public Offering Of 6,562,500 Shares Of Common Stock And Common Warrants At A Combined Price Of $0.80
Organovo Holdings, Inc. Announced the pricing of a public offering of 6,562,500 shares of its common stock. The gross proceeds from the offering are expected to be $5.25 million. The offering is expected to close in May 2024. Organovo is a clinical stage biotechnology company focused on developing novel treatment approaches.
Benzinga · 05/09 00:09
*Organovo Holdings' Offering of 6.6 Million Shares and Warrants Prices at 80 Cents a Share and Warrant
Dow Jones · 05/09 00:03
*Organovo Holdings Announces Pricing of $5.25M Public Offering
Dow Jones · 05/09 00:02
ORGANOVO HOLDINGS, INC. ANNOUNCES PRICING OF $5.25 MILLION PUBLIC OFFERING
Reuters · 05/09 00:00
Press Release: Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings, Inc. Announces Pricing of $5.25 million public offering. Organovo is a clinical stage biotechnology company focused on developing novel treatment approaches in three-dimensional human tissues. The company's lead molecule, FXR314, is on the path for Phase 2 in inflammatory bowel disease.
Dow Jones · 05/09 00:00
GME, ONVO and POAI among pre-market losers
GlycoMimetics -78% announces results of phase 3 study of Uproleselan in refractory. Meta Materials -30% to lay off 80% of its employees. Safe & Green Holdings Corp -24% announces pricing of $4 million private placement. GME, ONVO and POAI among pre-market losers.
Seeking Alpha · 05/06 12:26
Weekly Report: what happened at ONVO last week (0429-0503)?
Weekly Report · 05/06 11:09
Organovo Holdings Shares Corporate Update Presentation
TipRanks · 05/01 12:23
Weekly Report: what happened at ONVO last week (0422-0426)?
Weekly Report · 04/29 11:16
Weekly Report: what happened at ONVO last week (0415-0419)?
Weekly Report · 04/22 11:05
More
Webull provides a variety of real-time ONVO stock news. You can receive the latest news about Organovo Holding through multiple platforms. This information may help you make smarter investment decisions.
About ONVO
Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.